Soleus Capital Management, L.P. Cardiff Oncology, Inc. Transaction History

Soleus Capital Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 16, 2021	SELL	$6.65 - $10.04 $283,848 - $428,547	-42,684 Closed	0 $0
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $129,447 - $278,383	-14,225 Reduced 25.0%	42,684 $395,000
Q4 2020 Feb 16, 2021	SELL	$12.02 - $24.71 $2.7 Million - $5.56 Million	-224,910 Reduced 79.81%	56,909 $1.02 Million
Q3 2020 Nov 13, 2020	BUY	$4.25 - $14.19 $1.2 Million - $4 Million	281,819 New	281,819 $4 Million

124

29M

900K

234K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $162M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.